Alvotech Lines Up FDA Inspection Ahead Of Adalimumab Action
Reinspection Of Reykjavik Plant Scheduled For 6 March, Ahead Of 13 April Goal Date
Alvotech has secured a US FDA reinspection of its Reykjavik plant in March, ahead of the agency’s April goal date for action on the firm’s pending application for a high-concentration, interchangeable adalimumab biosimilar rival to Humira.
You may also be interested in...
What’s Next? Five Things To Look Out For In March
Prepare for all the biggest industry actions and events in March 2023 with Generics Bulletin’s monthly column.
Teva Will Stick To Hybrid Biosimilar Model, With Cash In Its Thinking
Teva’s senior management spoke at length about the company’s ambitions in the biosimilar space, ahead of the planned US launch of partner Alvotech’s AVT02 proposed interchangeable high-concentration (Humira) adalimumab biosimilar on 1 July.
Teva Hopes For Revenue Growth For First Time Since 2017
The company’s new CEO Richard Francis is aiming for revenue growth this year; it would be the first time since 2017.